标题：Effects of various doses of atorvastatin on vascular endothelial cell apoptosis and autophagy in vitro
作者：Zhao, Wen-Bo; Fu, Hui; Chang, Fen; Liu, Jing; Wang, Jinlan; Li, Fang; Zhao, Jing
作者机构：[Zhao, Wen-Bo] Shandong Univ, Dept Hematol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.; [Zhao, Wen-Bo; Fu, Hui; Chang, Fen; Liu, J 更多
通讯作者地址：[Zhao, J]Shandong Univ, Sch Life Sci, Shandong Prov Key Lab Anim Cells & Dev Biol, 27 South Shanda Rd, Jinan 250100, Shandong, Peoples R China.
来源：MOLECULAR MEDICINE REPORTS
关键词：atorvastatin; vascular endothelial cell; apoptosis; autophagy
摘要：Atorvastatin (Lipitor) is a lipid-lowering agent that is widely used in the treatment of cardiovascular diseases. Previous research has largely focused on its cholesterol-lowering effects; however, a limited number of studies have investigated the actions of atorvastatin on vascular endothelial cells. In the present study, the effects of various doses of atorvastatin were investigated on human umbilical vein endothelial cells (HUVECs). HUVECs were treated with various concentrations of atorvastatin in serum-free or serum-containing medium, and alterations in HUVEC morphology were observed. Cell survival and necrosis rates were evaluated using sulforhodamine B and lactate dehydrogenase assays, respectively. In addition, the protein expression levels of cellular apoptosis and autophagy markers were detected using western blot analysis. The results revealed that HUVEC morphology was altered following treatment with various concentrations of atorvastatin. In addition, autophagy was demonstrated to be induced by atorvastatin treatment at all concentrations, whereas high concentrations appeared to induce apoptosis and suppress the survival of HUVECs. In conclusion, the results of the present study suggested that various doses of atorvastatin may exert differential effects on HUVECs, and high doses may suppress angiogenesis. Therefore, atorvastatin may present a novel potential anti-tumor therapeutic strategy. However, further studies are required to fully elucidate the association between the dose of atorvastatin and its clinical outcome.